Table 1.21 U.S. Prevalence Counts, Invasive Cancers Only, January 1, 2009<sup>a</sup> Using Different Tumor Inclusion Criteriab

5-Year Limited Duration

34-year Limited Duration

Site	Sex	1st Invasive Tumor Ever <sup>c</sup>	1st Per Site in Previous 34 Years <sup>d</sup>	lst Per Site in Previous 5 Years <sup>e</sup>	1st Invasive Tumor Ever <sup>c</sup>	lst Per Site in Previous 34 Years <sup>d</sup>
All Sites	Both Sexes	4,357,341	4,442,261	4,864,827	12,096,978	12,304,118
	Male	2,246,570	2,279,828	2,484,619	5,717,465	5,784,750
	Female	2,110,771	2,162,433	2,380,208	6,379,513	6,519,368
Oral Cavity & Pharynx	Both Sexes Male Female	97,542 67,675 29,867	111,817 76,701 35,116	115,695 79,161 36,534	252,887 166,069 86,818	278,231 180,884 97,347
Esophagus	Both Sexes	20,356	24,677	24,737	31,710	37,085
	Male	15,922	19,308	19,356	24,602	28,647
	Female	4,434	5,369	5,381	7,108	8,438
Stomach	Both Sexes	34,419	40,930	41,143	68,386	78,221
	Male	20,553	24,756	24,854	38,804	44,783
	Female	13,866	16,174	16,289	29,582	33,438
Colon & Rectum	Both Sexes	405,797	469,194	478,203	1,111,907	1,239,920
	Male	205,558	237,798	242,129	548,761	608,653
	Female	200,239	231,396	236,074	563,146	631,267
Liver &	Both Sexes	26,017	29,875	29,931	35,119	39,545
Intrahepatic	Male	18,881	21,432	21,488	24,549	27,385
Bile Duct	Female	7,136	8,443	8,443	10,570	12,160
Pancreas	Both Sexes	28,875	35,140	35,140	37,971	45,129
	Male	14,376	17,768	17,768	18,446	22,163
	Female	14,499	17,372	17,372	19,525	22,966
Larynx	Both Sexes	30,294	36,780	37,134	86,894	97,654
	Male	24,153	29,235	29,544	69,765	77,999
	Female	6,141	7,545	7,590	17,129	19,655
Lung & Bronchus	Both Sexes	224,508	284,065	291,615	379,223	462,713
	Male	104,519	133,787	136,648	173,619	212,377
	Female	119,989	150,278	154,967	205,604	250,336
Melanoma of the Skin	Both Sexes Male Female	263,883 140,746 123,137	297,561 162,207 135,354	309,968 170,141 139,827	837,215 415,003 422,212	901,518 452,508 449,010
Breast	Female	818,223	883,935	937,301	2,681,040	2,841,885
Cervix	Female	37,983	39,767	39,882	202,962	208,595
Corpus & Uterus, NOS	Female	160,329	180,638	180,713	553,870	603,503
Ovary <sup>f</sup>	Female	55,497	64,242	64,294	164,877	185,160

U.S. 2009 cancer prevalence counts are based on 2009 cancer prevalence proportions from the SEER 9 registries and 1/1/2009 U.S. population estimates based on the average of 2008 and 2009 population estimates from the U.S. Bureau of the Census.

d

b Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion:

<sup>(</sup>c) First invasive tumor ever
(d) First invasive tumor for each cancer site diagnosed during the previous 34 years (1975-2008)
(e) First invasive tumor for each cancer site diagnosed during the previous 5 years (2004-2008)
For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2004;

Melanoma in 2005.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 34-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2009. In method (d) the 1981 melanoma is counted for the melanoma and all sites 34-year limited duration prevalence. The 2004 breast cancer is counted for the breast 5-year and 34-year limited duration prevalence.

In method (e) the 2004 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2005 melanoma is counted for 5-year limited duration prevalence for melanoma.

Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

## Table 1.21 - continued U.S. Prevalence Counts, Invasive Cancers Only, January 1, 2009<sup>a</sup> Using Different Tumor Inclusion Criteriab

5-Year Limited Duration

34-year Limited Duration

Site	Sex	lst Invasive Tumor Ever <sup>c</sup>	lst Per Site in Previous 34 Years <sup>d</sup>	lst Per Site in Previous 5 Years <sup>e</sup>	lst Invasive Tumor Ever <sup>c</sup>	1st Per Site in Previous 34 Years <sup>d</sup>
Prostate	Male	991,610	1,069,850	1,069,879	2,494,988	2,659,051
Testis	Male	41,292	42,052	42,698	194,935	197,533
Urinary Bladder	Both Sexes	196,403	243,253	248,175	540,518	626,417
	Male Female	148,936 47,467	185,112 58,141	189,064 59,111	402,281 138,237	466,103 160,314
Kidney &	Both Sexes	137,327	166,272	168,023	309,168	359,955
Renal Pelvis	Male Female	82,513 54,814	101,559 64,713	102,846 65,177	182,285 126,883	214,227 145,728
Brain &	Both Sexes	42,492	44,665	45,128	121,848	125,138
Nervous System	Male Female	23,270 19,222	24,518 20,147	24,750 20,378	64,666 57,182	66,457 58,681
Thyroid	Both Sexes	150,696	166,265	166,781	456,180	484,996
	Male Female	33,895 116,801	39,037 127,228	39,179 127,602	99,597 356,583	108,060 376,936
Hodgkin Lymphoma	Both Sexes	37,947	40,392	40,402	161,071	165,355
	Male Female	20,359 17,588	21,735 18,657	21,735 18,667	83,458 77,613	85,731 79,624
Non-Hodgkin	Both Sexes	193,568	226,608	228,204	474,455	529,222
Lymphoma	Male Female	101,809 91,759	120,766 105,842	121,658 106,546	246,926 227,529	276,020 253,202
Myeloma	Both Sexes Male	45,747	53,626	53,674	70,950	81,089
	Male Female	24,230 21,517	28,956 24,670	28,992 24,682	38,319 32,631	44,359 36,730
Leukemia	Both Sexes	108,472	124,139	124,315	266,026	291,521
	Male Female	62,188 46,284	71,959 52,180	72,042 52,273	150,062 115,964	165,245 126,276
Acute Lymphocytic	Both Sexes Male	15,984 9,278	16,396 9,448	16,396 9,448	62,732 34,732	63,353 34,950
Leukemia	Female	6,706	6,948	6,948	28,000	28,403
Childhood (Ages 0-19)	Both Sexes Male	61,498 32,966	61,622 33,016	62,135 33,253	288,648 148,843	289,141 149,048
(Ages U-I)	Female	28,532	28,606	28,882	139,805	140,093
Kaposi Sarcoma	Both Sexes Male	7,129 6,715	7,546 7,047	7,546 7,047	23,623 22,336	24,764 23,276
	Female	414	499	499	1,287	1,488
Mesothelioma	Both Sexes Male	3,040 2,095	3,957 2,759	3,957 2,759	4,570 2,694	5,673 3,484
	Female	945	1,198	1,198	1,876	2,189

U.S. 2009 cancer prevalence counts are based on 2009 cancer prevalence proportions from the SEER 9 registries and 1/1/2009 U.S. population estimates based on the average of 2008 and 2009 population estimates from the U.S. Bureau of the Census.

d

Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion:

(c) First invasive tumor ever

(d) First invasive tumor for each cancer site diagnosed during the previous 34 years (1975-2008)

(e) First invasive tumor for each cancer site diagnosed during the previous 5 years (2004-2008)

For definitions (d) and (e) all sites is treated as a separate cancer "site"

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2004;

Melanoma in 2005.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 34-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2009. In method (d) the 1981 melanoma is counted for the melanoma and all sites 34-year limited duration prevalence. The 2004 breast cancer is counted for the breast 5-year and 34-year limited duration prevalence.

In method (e) the 2004 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2005 melanoma is counted for 5-year limited duration prevalence for melanoma.

Table 1.22 U.S. Complete Prevalence Counts, Invasive Cancers Only, January 1, 2009a By Age at Prevalence

	Age at Prevalence								
Site/Sex	All Ages <sup>c</sup>	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70+
211 011									
All Sites Males	5,809,017	18,156	41,323	80,500	150,710	346,280	815,636	1,465,844	2,890,567
		18,156							
Females	6,740,016	15,649	35,203	83,134	219,550	622,449	1,226,028	1,600,054	2,937,950
Oral Cavity & Pharynx									
Males	172,502	67	418	1,505	3,416	14,153	41,881	49,752	61,309
Females	91,610	101	493	1,453	3,530	8,334	17,445	21,205	39,049
Esophagus									
Males	24,657	0	0	38	186	1,059	4,426	8,360	10,588
Females	7,170	0	0	0	39	314	1,070	1,656	4,091
Stomach									
Males	39,694	0	17	78	688	2,436	6,519	9,680	20,275
Females	30,232	4	11	165	643	2,169	4,233	5,764	17,243
	,					_,	-,	2,	,
Colon & Rectum									
Males	558,408	11	69	1,116	5,277	24,270	77,071	129,789	320,804
Females	581,302	0	86	1,202	5,090	22,495	64,292	107,339	380,797
Liver & Intrahep									
Males	24,615	438	554	494	438	1,581	8,481	7,111	5,516
Females	10,913	466	435	332	473	786	2,384	2,609	3,430
Pancreas									
Males	18,537	0	23	68	321	1,356	4,100	5,731	6,939
Females	19,649	0	47	135	418	1,377	3,454	5,181	9,036
Larynx									
Males	71,550	0	0	66	221	2,095	10,475	20,267	38,425
Females	17,521	0	0	48	143	1,051	3,163	4,474	8,642
Lung & Bronchus									
Males	178,447	45	80	454	1,086	5,587	24,209	52,348	94,640
Females	209,203	34	47	363	1,291	7,893	27,437	57,808	114,331
1 Smales	200,200	51	± ,	303	1,271	,,000	2,,13,	37,000	111,551
Melanoma of the Skin									
Males	427,519	72	764	5,002	17,503	47,272	91,489	111,843	153,573
Females	448,192	95	950	10,770	33,163	72,253	104,576	99,252	127,133

U.S. 2009 cancer prevalence counts are based on 2009 cancer prevalence proportions from the SEER 9 registries (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta) and 1/1/2009 U.S. population estimates based on the average of 2008 and 2009 population estimates from the U.S. Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

Cases diagnosed more than 34 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

Due to rounding, the sum of the age specific estimates may not equal the all ages estimate.

Table 1.22 - continued U.S. Complete Prevalence Counts, Invasive Cancers Only, January 1, 2009ª By Age at Prevalence

Recast		Age at Prevalence								
Males Females         14,303 (2,747,209)         0         86         22 (2,487)         103 (35,884)         212,685         2,093 (33,896)         7,691 (7,691)           Cervix Females         247,556         0         68         2,050         16,434         42,782         59,350         52,979         73,893           Corpus & Uterus, NOS Females         589,789         0         56         412         5,572         24,294         82,675         148,774         328,006           Ovary <sup>4</sup> Females         182,710         66         932         3,503         6,560         19,171         39,536         45,524         67,418           Prostate Males         2,496,420         34         69         89         247         19,652         216,595         687,644         1,572,090           Urinary Bladder Males         411,161         56         110         595         2,405         11,643         42,320         94,909         259,122           Females         143,089         34         56         150         12,405         1,613         37,165         53,360         70,087           Remales         188,341         1,507         2,373         2,601         4,936         16,313         37,165 <t< th=""><th>Site/Sex</th><th>All Ages<sup>c</sup></th><th>0-9</th><th>10-19</th><th>20-29</th><th>30-39</th><th>40-49</th><th>50-59</th><th>60-69</th><th>70+</th></t<>	Site/Sex	All Ages <sup>c</sup>	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70+
Males Females         14,303 (2,747,209)         0         86         22 (2,487)         103 (35,884)         212,685         2,093 (33,896)         7,691 (7,691)           Cervix Females         247,556         0         68         2,050         16,434         42,782         59,350         52,979         73,893           Corpus & Uterus, NOS Females         589,789         0         56         412         5,572         24,294         82,675         148,774         328,006           Ovary <sup>4</sup> Females         182,710         66         932         3,503         6,560         19,171         39,536         45,524         67,418           Prostate Males         2,496,420         34         69         89         247         19,652         216,595         687,644         1,572,090           Urinary Bladder Males         411,161         56         110         595         2,405         11,643         42,320         94,909         259,122           Females         143,089         34         56         150         12,405         1,613         37,165         53,360         70,087           Remales         188,341         1,507         2,373         2,601         4,936         16,313         37,165 <t< td=""><td>Projet</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>	Projet									
Pemales   2,747,209   0   86   2,487   35,584   212,685   522,225   733,979   1,240,161		1/1 2/12	0	0	2.2	102	100	2 002	2 006	7 601
Cervix Females 247,556 0 68 2,050 16,434 42,782 59,350 52,979 73,893   Corpus & Uterus, NOS Females 589,789 0 56 412 5,572 24,294 82,675 148,774 328,006   Ovarya Females 182,710 66 932 3,503 6,560 19,171 39,536 45,524 67,418   Frostate Males 2,496,420 34 69 89 247 19,552 216,595 687,644 1,572,090   Urinary Bladder Males 111,161 56 110 595 2,405 11,643 42,320 94,909 259,122   Fremales 188,341 1,507 2,373 2,601 4,926 16,313 37,165 53,360 70,087   Fremales 188,341 1,507 2,373 2,601 4,926 16,313 37,165 53,360 70,087   Fremales 90,420 168 2,316 9,264 16,301 23,466 20,120 12,217 6,567   Fremales 90,420 168 2,316 9,264 16,301 23,466 20,120 12,217 6,567   Fremales 90,420 168 2,316 9,264 16,301 23,466 20,120 12,217 6,567   Fremales 90,420 168 2,316 9,264 16,301 23,466 20,120 12,217 6,567   Fremales 90,420 168 2,316 9,264 16,301 23,466 20,120 12,217 6,567   Fremales 90,420 168 2,316 9,264 16,301 23,466 20,120 12,217 6,567   Fremales 90,420 168 2,316 9,264 16,301 23,466 20,120 12,217 6,567   Fremales 90,420 168 2,316 9,264 16,301 23,466 20,120 12,217 6,567   Fremales 90,420 168 2,316 9,264 16,301 23,466 20,120 12,217 6,567   Fremales 90,420 168 2,316 9,264 16,301 23,466 20,120 12,217 6,567   Fremales 90,420 168 2,316 9,264 16,301 23,466 20,120 12,217 6,567   Fremales 90,420 168 9,320 10,420 9,767 16,451 1,450 18,024 9,332 9,309 10,468   Fremales 90,420 168 9,340 1,402 9,767 16,451 1,402 19,927 1,402 10,468   Fremales 90,420 168 9,340 1,402									•	,
Pemales   247,556   08   68   2,050   16,434   42,782   59,350   52,979   73,938   Corpus & Uterus, NOS Pemales   589,789   08   556   412   5,572   24,294   82,675   148,774   328,006	remaies	2,747,209	U	00	2,40/	33,304	212,005	522,225	133,919	1,240,161
Corpus & Uterus, NOS   Females   589,789   0   56   412   5,572   24,294   82,675   148,774   328,006	Cervix									
Females         589,789         0         56         412         5,572         24,294         82,675         148,774         328,006           Ovary <sup>6</sup> Females         182,710         66         932         3,503         6,560         19,171         39,536         45,524         67,418           Prostate Males         2,496,420         34         69         89         247         19,652         216,595         687,644         1,772,090           Urinary Bladder Males         411,161         56         110         595         2,405         11,643         42,320         94,909         259,122           Females         143,089         34         56         162         1,087         4,412         13,373         29,661         94,303           Kidney & Renal Pelvis Males         188,341         1,507         2,373         2,601         4,936         16,313         37,165         53,360         70,087           Females         131,799         1,408         2,607         2,769         4,642         11,613         37,165         53,360         70,087           Hodgkin Lymphoma Males         99,420         168         2,316         9,264         16,301         23,466         20,120         12	Females	247,556	0	68	2,050	16,434	42,782	59,350	52,979	73,893
Females         589,789         0         56         412         5,572         24,294         82,675         148,774         328,006           Ovary <sup>6</sup> Females         182,710         66         932         3,503         6,560         19,171         39,536         45,524         67,418           Prostate Males         2,496,420         34         69         89         247         19,652         216,595         687,644         1,772,090           Urinary Bladder Males         411,161         56         110         595         2,405         11,643         42,320         94,909         259,122           Females         143,089         34         56         162         1,087         4,412         13,373         29,661         94,303           Kidney & Renal Pelvis Males         188,341         1,507         2,373         2,601         4,936         16,313         37,165         53,360         70,087           Females         131,799         1,408         2,607         2,769         4,642         11,613         37,165         53,360         70,087           Hodgkin Lymphoma Males         99,420         168         2,316         9,264         16,301         23,466         20,120         12	Corpus & Uterus, NOS									
Pemales   182,710   66   932   3,503   6,560   19,171   39,536   45,524   67,418		589,789	0	56	412	5,572	24,294	82,675	148,774	328,006
Females   182,710   66   932   3,503   6,560   19,171   39,536   45,524   67,418		2227.22				-,	,	,		5_2,555
Prostate Males 2,496,420 34 69 89 247 19,652 216,595 687,644 1,572,090  Urinary Bladder	_									
Males 2,496,420 34 69 89 247 19,652 216,595 687,644 1,572,090  Urinary Bladder Males 411,161 56 110 595 2,405 11,643 42,320 94,909 259,122  Females 143,089 34 56 162 1,087 4,412 13,373 29,661 94,303  Kidney & Renal Pelvis Males 188,341 1,507 2,373 2,601 4,936 16,313 37,165 53,360 70,087 Females 131,799 1,408 2,607 2,769 4,642 11,613 22,637 30,925 55,198  Hodgkin Lymphoma Males 90,420 168 2,316 9,264 16,301 23,466 20,120 12,217 6,567 Females 84,475 146 1,642 9,767 16,451 22,548 18,024 9,302 6,597  Non-Hodgkin Lymphoma Males 252,012 810 3,472 7,162 12,801 28,228 49,236 62,729 87,574 Females 232,051 387 1,793 4,203 8,302 19,927 39,219 53,951 104,268  Myeloma Males 38,403 0 66 550 485 2,628 7,535 12,343 15,356 Females 38,403 0 0 66 50 485 2,628 7,535 12,343 15,356 Females 32,754 0 0 0 22 276 2,112 5,612 9,822 14,911  Leukemia Males 152,597 6,389 12,636 11,647 10,425 12,678 20,796 29,694 48,332 Females 152,597 6,389 12,636 11,647 10,425 12,678 20,796 29,694 48,332 Females 36,576 5,244 10,969 9,000 5,888 3,114 1,140 773 4448	Females	182,710	66	932	3,503	6,560	19,171	39,536	45,524	67,418
Urinary Bladder           Males (Males)         411,161 (Males)         56 (Males)         110 (Males)         2,405 (Males)         11,643 (Males)         42,320 (Males)         94,909 (Males)         259,122 (Males)           Kidney & Renal Pelvis (Males)         188,341 (Males)         1,507 (Males)         2,373 (Males)         2,601 (Males)         4,936 (Males)         16,313 (Males)         37,165 (Males)         53,360 (Males)         70,087 (Males)         55,198 (Males)         131,799 (Males)         1,408 (Males)         2,601 (Males)         4,936 (Males)         16,313 (Males)         37,165 (Males)         53,360 (Males)         70,087 (Males)         55,198 (Males)         1,657 (Males)         55,198 (Males)         1,657 (Males)         1,657 (Males)         1,657 (Males)         1,657 (Males)         1,657 (Males)         1,658 (Males)         1,658 (Males)         1,647 (Males)         1,641 (Males)         1,642 (Males)         1,757 (Males) </td <td>Prostate</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	Prostate									
Males 411,161 56 110 595 2,405 11,643 42,320 94,909 259,122 Females 143,089 34 56 162 1.087 4,412 13,373 29,661 94,303   Kidney & Renal Pelvis Males 188,341 1,507 2,373 2,601 4,936 16,313 37,165 53,360 70,087 Females 131,799 1,408 2,607 2,769 4,642 11,613 22,637 30,925 55,198   Hodgkin Lymphoma Males 90,420 168 2,316 9,264 16,301 23,466 20,120 12,217 6,567 Females 84,475 146 1,642 9,767 16,451 22,548 18,024 9,302 6,597   Non-Hodgkin Lymphoma Males 252,012 810 3,472 7,162 12,801 28,228 49,236 62,729 87,574 Females 232,051 387 1,793 4,203 8,302 19,927 39,219 53,951 104,268   Myeloma Males 38,403 0 6 50 485 2,628 7,535 12,343 15,356 Females 32,754 0 0 0 22 276 2,112 5,612 9,822 14,911   Leukemia Males 152,597 6,389 12,636 11,647 10,425 12,678 20,796 29,694 48,332 Females 119,096 5,232 10,502 10,167 9,042 9,418 13,463 19,494 41,777   Accute Lymphocytic Leuk Males 36,576 5,244 10,969 9,000 5,888 3,114 1,140 773 448	Males	2,496,420	34	69	89	247	19,652	216,595	687,644	1,572,090
Males 411,161 56 110 595 2,405 11,643 42,320 94,909 259,122 Females 143,089 34 56 162 1.087 4,412 13,373 29,661 94,303   Kidney & Renal Pelvis Males 188,341 1,507 2,373 2,601 4,936 16,313 37,165 53,360 70,087 Females 131,799 1,408 2,607 2,769 4,642 11,613 22,637 30,925 55,198   Hodgkin Lymphoma Males 90,420 168 2,316 9,264 16,301 23,466 20,120 12,217 6,567 Females 84,475 146 1,642 9,767 16,451 22,548 18,024 9,302 6,597   Non-Hodgkin Lymphoma Males 252,012 810 3,472 7,162 12,801 28,228 49,236 62,729 87,574 Females 232,051 387 1,793 4,203 8,302 19,927 39,219 53,951 104,268   Myeloma Males 38,403 0 6 50 485 2,628 7,535 12,343 15,356 Females 32,754 0 0 0 22 276 2,112 5,612 9,822 14,911   Leukemia Males 152,597 6,389 12,636 11,647 10,425 12,678 20,796 29,694 48,332 Females 119,096 5,232 10,502 10,167 9,042 9,418 13,463 19,494 41,777   Accute Lymphocytic Leuk Males 36,576 5,244 10,969 9,000 5,888 3,114 1,140 773 448	Urinarv Bladder									
Females 143,089 34 56 162 1,087 4,412 13,373 29,661 94,303  Kidney & Renal Pelvis Males 188,341 1,507 2,373 2,601 4,936 16,313 37,165 53,360 70,087 Females 131,799 1,408 2,607 2,769 4,642 11,613 22,637 30,925 55,198  Hodgkin Lymphoma Males 90,420 168 2,316 9,264 16,301 23,466 20,120 12,217 6,567 Females 84,475 146 1,642 9,767 16,451 22,548 18,024 9,302 6,597  Non-Hodgkin Lymphoma Males 252,012 810 3,472 7,162 12,801 28,228 49,236 62,729 87,574 Females 232,051 387 1,793 4,203 8,302 19,927 39,219 53,951 104,268  Myeloma Males 38,403 0 6 5 5 485 2,628 7,535 12,343 15,356 Females 32,754 0 0 0 22 276 2,112 5,612 9,822 14,911  Leukemia Males 152,597 6,389 12,636 11,647 10,425 12,678 20,796 29,694 48,332 Females 119,096 5,232 10,502 10,167 9,042 9,418 13,463 19,494 41,777  Acute Lymphocytic Leuk Males 36,576 5,244 10,969 9,000 5,888 3,114 1,140 773 448	-	411.161	56	110	595	2.405	11.643	42.320	94.909	259.122
Kidney & Renal Pelvis Males 188,341 1,507 2,373 2,601 4,936 16,313 37,165 53,360 70,087 Females 131,799 1,408 2,607 2,769 4,642 11,613 22,637 30,925 55,198  Hodgkin Lymphoma Males 90,420 168 2,316 9,264 16,301 23,466 20,120 12,217 6,567 Females 84,475 146 1,642 9,767 16,451 22,548 18,024 9,302 6,597  Non-Hodgkin Lymphoma Males 252,012 810 3,472 7,162 12,801 28,228 49,236 62,729 87,574 Females 232,051 387 1,793 4,203 8,302 19,927 39,219 53,951 104,268  Myeloma Males 38,403 0 6 50 485 2,628 7,535 12,343 15,356 Females 32,754 0 0 2 2 276 2,112 5,612 9,822 14,911  Leukemia Males 152,597 6,389 12,636 11,647 10,425 12,678 20,796 29,694 48,332 Females 19,096 5,232 10,502 10,167 9,042 9,418 13,463 19,494 41,777  Accute Lymphocytic Leuk Males 36,576 5,244 10,969 9,000 5,888 3,114 1,140 773 448									•	•
Males 188,341 1,507 2,373 2,601 4,936 16,313 37,165 53,360 70,087 Females 131,799 1,408 2,607 2,769 4,642 11,613 22,637 30,925 55,198   Hodgkin Lymphoma	1 Chicares	113,000	31	30	102	1,007	1,112	13,373	25,001	71,303
Females         131,799         1,408         2,607         2,769         4,642         11,613         22,637         30,925         55,198           Hodgkin Lymphoma         Males         90,420         168         2,316         9,264         16,301         23,466         20,120         12,217         6,567           Females         84,475         146         1,642         9,767         16,451         23,466         20,120         12,217         6,567           Non-Hodgkin Lymphoma         Males         252,012         810         3,472         7,162         12,801         28,228         49,236         62,729         87,574           Females         232,051         387         1,793         4,203         8,302         19,927         39,219         53,951         104,268           Myeloma         Males         38,403         0         6         50         485         2,628         7,535         12,343         15,356           Females         32,754         0         0         22         276         2,112         5,612         9,822         14,911           Leukemia         Males         152,597         6,389         12,636         11,647         10,425         12,67	-									
Hodgkin Lymphoma Males 90,420 168 2,316 9,264 16,301 23,466 20,120 12,217 6,567 Females 84,475 146 1,642 9,767 16,451 22,548 18,024 9,302 6,597  Non-Hodgkin Lymphoma Males 252,012 810 3,472 7,162 12,801 28,228 49,236 62,729 87,574 Females 232,051 387 1,793 4,203 8,302 19,927 39,219 53,951 104,268  Myeloma Males 38,403 0 6 50 485 2,628 7,535 12,343 15,356 Females 32,754 0 0 0 22 276 2,112 5,612 9,822 14,911  Leukemia Males 152,597 6,389 12,636 11,647 10,425 12,678 20,796 29,694 48,332 Females 119,096 5,232 10,502 10,167 9,042 9,418 13,463 19,494 41,777  Acute Lymphocytic Leuk Males 36,576 5,244 10,969 9,000 5,888 3,114 1,140 773 448					•	•		•	•	•
Males 90,420 168 2,316 9,264 16,301 23,466 20,120 12,217 6,567 Females 84,475 146 1,642 9,767 16,451 22,548 18,024 9,302 6,597    Non-Hodgkin Lymphoma	Females	131,799	1,408	2,607	2,769	4,642	11,613	22,637	30,925	55,198
Females         84,475         146         1,642         9,767         16,451         22,548         18,024         9,302         6,597           Non-Hodgkin Lymphoma         Males         252,012         810         3,472         7,162         12,801         28,228         49,236         62,729         87,574           Females         232,051         387         1,793         4,203         8,302         19,927         39,219         53,951         104,268           Myeloma         Males         38,403         0         6         50         485         2,628         7,535         12,343         15,356           Females         32,754         0         0         22         276         2,112         5,612         9,822         14,911           Leukemia         Males         152,597         6,389         12,636         11,647         10,425         12,678         20,796         29,694         48,332           Females         119,096         5,232         10,502         10,167         9,042         9,418         13,463         19,494         41,777           Acute Lymphocytic Leuk         Males         36,576         5,244         10,969	Hodgkin Lymphoma									
Non-Hodgkin Lymphoma Males 252,012 810 3,472 7,162 12,801 28,228 49,236 62,729 87,574 Females 232,051 387 1,793 4,203 8,302 19,927 39,219 53,951 104,268  Myeloma Males 38,403 0 6 50 485 2,628 7,535 12,343 15,356 Females 32,754 0 0 0 22 276 2,112 5,612 9,822 14,911  Leukemia Males 152,597 6,389 12,636 11,647 10,425 12,678 20,796 29,694 48,332 Females 119,096 5,232 10,502 10,167 9,042 9,418 13,463 19,494 41,777  Acute Lymphocytic Leuk Males 36,576 5,244 10,969 9,000 5,888 3,114 1,140 773 448		90,420	168	2,316	9,264	16,301	23,466	20,120	12,217	6,567
Males         252,012         810         3,472         7,162         12,801         28,228         49,236         62,729         87,574           Females         232,051         387         1,793         4,203         8,302         19,927         39,219         53,951         104,268           Myeloma           Males         38,403         0         6         50         485         2,628         7,535         12,343         15,356           Females         32,754         0         0         22         276         2,112         5,612         9,822         14,911           Leukemia           Males         152,597         6,389         12,636         11,647         10,425         12,678         20,796         29,694         48,332           Females         119,096         5,232         10,502         10,167         9,042         9,418         13,463         19,494         41,777           Acute Lymphocytic Leuk           Males         36,576         5,244         10,969         9,000         5,888         3,114         1,140         773         448	Females	84,475	146	1,642	9,767	16,451	22,548	18,024	9,302	6,597
Males         252,012         810         3,472         7,162         12,801         28,228         49,236         62,729         87,574           Females         232,051         387         1,793         4,203         8,302         19,927         39,219         53,951         104,268           Myeloma           Males         38,403         0         6         50         485         2,628         7,535         12,343         15,356           Females         32,754         0         0         22         276         2,112         5,612         9,822         14,911           Leukemia           Males         152,597         6,389         12,636         11,647         10,425         12,678         20,796         29,694         48,332           Females         119,096         5,232         10,502         10,167         9,042         9,418         13,463         19,494         41,777           Acute Lymphocytic Leuk           Males         36,576         5,244         10,969         9,000         5,888         3,114         1,140         773         448	Name Hadalain Tamunhama									
Females         232,051         387         1,793         4,203         8,302         19,927         39,219         53,951         104,268           Myeloma         Males         38,403         0         6         50         485         2,628         7,535         12,343         15,356           Females         32,754         0         0         22         276         2,112         5,612         9,822         14,911           Leukemia         Males         152,597         6,389         12,636         11,647         10,425         12,678         20,796         29,694         48,332           Females         119,096         5,232         10,502         10,167         9,042         9,418         13,463         19,494         41,777           Acute Lymphocytic Leuk         Males         36,576         5,244         10,969         9,000         5,888         3,114         1,140         773         448		252 012	010	2 472	7 160	10 001	20 220	10 226	62 720	07 574
Myeloma Males 38,403 0 6 50 485 2,628 7,535 12,343 15,356 Females 32,754 0 0 22 276 2,112 5,612 9,822 14,911  Leukemia Males 152,597 6,389 12,636 11,647 10,425 12,678 20,796 29,694 48,332 Females 119,096 5,232 10,502 10,167 9,042 9,418 13,463 19,494 41,777  Acute Lymphocytic Leuk Males 36,576 5,244 10,969 9,000 5,888 3,114 1,140 773 448										•
Males       38,403       0       6       50       485       2,628       7,535       12,343       15,356         Females       32,754       0       0       22       276       2,112       5,612       9,822       14,911         Leukemia       Males       152,597       6,389       12,636       11,647       10,425       12,678       20,796       29,694       48,332         Females       119,096       5,232       10,502       10,167       9,042       9,418       13,463       19,494       41,777         Acute Lymphocytic Leuk         Males       36,576       5,244       10,969       9,000       5,888       3,114       1,140       773       448	remaies	232,031	367	1,793	4,203	0,302	19,927	39,219	53,951	104,200
Females 32,754 0 0 0 22 276 2,112 5,612 9,822 14,911  Leukemia  Males 152,597 6,389 12,636 11,647 10,425 12,678 20,796 29,694 48,332  Females 119,096 5,232 10,502 10,167 9,042 9,418 13,463 19,494 41,777  Acute Lymphocytic Leuk  Males 36,576 5,244 10,969 9,000 5,888 3,114 1,140 773 448	Myeloma									
Leukemia  Males 152,597 6,389 12,636 11,647 10,425 12,678 20,796 29,694 48,332 Females 119,096 5,232 10,502 10,167 9,042 9,418 13,463 19,494 41,777  Acute Lymphocytic Leuk  Males 36,576 5,244 10,969 9,000 5,888 3,114 1,140 773 448	Males	38,403	0	6	50	485	2,628	7,535	12,343	15,356
Males 152,597 6,389 12,636 11,647 10,425 12,678 20,796 29,694 48,332 Females 119,096 5,232 10,502 10,167 9,042 9,418 13,463 19,494 41,777  Acute Lymphocytic Leuk Males 36,576 5,244 10,969 9,000 5,888 3,114 1,140 773 448	Females	32,754	0	0	22	276	2,112	5,612	9,822	14,911
Males 152,597 6,389 12,636 11,647 10,425 12,678 20,796 29,694 48,332 Females 119,096 5,232 10,502 10,167 9,042 9,418 13,463 19,494 41,777  Acute Lymphocytic Leuk Males 36,576 5,244 10,969 9,000 5,888 3,114 1,140 773 448	Leukemia									
Females 119,096 5,232 10,502 10,167 9,042 9,418 13,463 19,494 41,777  Acute Lymphocytic Leuk Males 36,576 5,244 10,969 9,000 5,888 3,114 1,140 773 448		152.597	6.389	12.636	11.647	10.425	12.678	20.796	29.694	48.332
Acute Lymphocytic Leuk Males 36,576 5,244 10,969 9,000 5,888 3,114 1,140 773 448				•	•	•		•	•	
Males 36,576 5,244 10,969 9,000 5,888 3,114 1,140 773 448		, , 0, 0	-,	_ = , , , , , ,	,	- , 0 12	- ,	,	, 1	,,
Females 29,614 4,381 8,829 7,398 4,995 2,241 767 687 315										
	Females	29,614	4,381	8,829	7,398	4,995	2,241	767	687	315

U.S. 2009 cancer prevalence counts are based on 2009 cancer prevalence proportions from the SEER 9 registries (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta) and 1/1/2009 U.S. population estimates based on the average of 2008 and 2009 population estimates from the U.S. Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

Cases diagnosed more than 34 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

Due to rounding, the sum of the age specific estimates may not equal the all ages estimate.